BR9509076A - Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano - Google Patents

Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano

Info

Publication number
BR9509076A
BR9509076A BR9509076A BR9509076A BR9509076A BR 9509076 A BR9509076 A BR 9509076A BR 9509076 A BR9509076 A BR 9509076A BR 9509076 A BR9509076 A BR 9509076A BR 9509076 A BR9509076 A BR 9509076A
Authority
BR
Brazil
Prior art keywords
human papillomavirus
pretein
disease
isolated
processes
Prior art date
Application number
BR9509076A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathryn J Hollmann
Kathrin U Jansen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23202654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9509076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9509076A publication Critical patent/BR9509076A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9509076A 1994-09-22 1995-09-18 Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano BR9509076A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31046894A 1994-09-22 1994-09-22
PCT/US1995/011859 WO1996009375A1 (fr) 1994-09-22 1995-09-18 Adn codant pour le papillomavirus humain du type 6a

Publications (1)

Publication Number Publication Date
BR9509076A true BR9509076A (pt) 1998-07-14

Family

ID=23202654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509076A BR9509076A (pt) 1994-09-22 1995-09-18 Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano

Country Status (16)

Country Link
US (1) US6290965B1 (fr)
EP (1) EP0782615A4 (fr)
JP (1) JPH10506014A (fr)
AU (1) AU694269B2 (fr)
BG (1) BG101338A (fr)
BR (1) BR9509076A (fr)
CA (1) CA2200582C (fr)
CZ (1) CZ87597A3 (fr)
FI (1) FI121507B (fr)
HU (1) HUT77337A (fr)
NO (1) NO971347L (fr)
NZ (1) NZ293461A (fr)
PL (1) PL319294A1 (fr)
RU (1) RU2177999C2 (fr)
SK (1) SK35897A3 (fr)
WO (1) WO1996009375A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962981B1 (en) * 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
PT1105466E (pt) * 1998-08-14 2006-07-31 Merck & Co Inc Processo para a purificacao de particulas tipo virus do papilomavirus humano
CN1100835C (zh) * 1998-10-30 2003-02-05 中国科学院感光化学研究所 加入纳米无机化合物粒子的钛溶胶－凝胶涂料及其制法和用途
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
WO2004081178A2 (fr) * 2003-03-06 2004-09-23 Indiana University Research And Technology Corporation Methodes et compositions pour produire des souches hpv infectieuses
IL156670A0 (en) * 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
US20090053261A1 (en) * 2005-09-08 2009-02-26 Lindbo John A Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
CA2588581C (fr) 2004-12-08 2011-05-31 Gen-Probe Incorporated Detection d'acides nucleiques de types multiples de papillomavirus humains
US8084207B2 (en) * 2005-03-03 2011-12-27 Ibis Bioscience, Inc. Compositions for use in identification of papillomavirus
US20070031826A1 (en) * 2005-08-05 2007-02-08 My Gene Diagnostic kit for determining the genotype of a human papilloma virus and method of using thereof
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
PT2227546T (pt) * 2007-12-21 2016-08-12 Novartis Ag Vector de expressão em mamíferos
WO2011149897A1 (fr) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Analyse de capture hybride à résultats rapides et sondes associées tronquées de manière stratégique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1835029A1 (fr) * 1992-06-25 2007-09-19 Georgetown University Vaccins de papillomavirus
JP3863559B2 (ja) * 1994-05-16 2006-12-27 メルク エンド カンパニー インコーポレーテッド 乳頭腫ウィルスワクチン
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein

Also Published As

Publication number Publication date
RU2177999C2 (ru) 2002-01-10
MX9702209A (es) 1997-07-31
NO971347D0 (no) 1997-03-21
AU3591895A (en) 1996-04-09
BG101338A (en) 1997-10-31
PL319294A1 (en) 1997-08-04
AU694269B2 (en) 1998-07-16
CA2200582C (fr) 2007-03-27
FI971203A0 (fi) 1997-03-21
FI971203A (fi) 1997-03-21
EP0782615A1 (fr) 1997-07-09
SK35897A3 (en) 1998-02-04
NO971347L (no) 1997-05-21
NZ293461A (en) 1998-04-27
HUT77337A (hu) 1998-03-30
US6290965B1 (en) 2001-09-18
CZ87597A3 (cs) 1998-01-14
FI121507B (fi) 2010-12-15
WO1996009375A1 (fr) 1996-03-28
JPH10506014A (ja) 1998-06-16
CA2200582A1 (fr) 1996-03-28
EP0782615A4 (fr) 2001-08-22

Similar Documents

Publication Publication Date Title
BR9509076A (pt) Molécula de dna isolada e purificada vetor de expressão proteína anticorpo monoespecífico composto composição farmacêutica vacina e processos para expressar preteina de papilomavírus humano tipo 6a para identificar compostos e para induzir respostas imunes contra infecção ou doença provocada por papilomavírus humano
BR0214137A (pt) Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos
PT712307E (pt) Metodos para controlo da populacao de celulas b
ATE348113T1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
BR9406007A (pt) Construção de DNA, vacina de polinucleotídeos, vetor, processos para proteger contra infecção por vírus influenza humano, para usar um gene de vírus influenza, para induzir respostas imunes contra infecção ou doença provocada por cepas de vírus influenza, composição de construções de ácido nucleico e uso de um gene de vírus influenza humano
BR9508596A (pt) Moduladores de peso de corpo correspondentes ácidos nucléicos e proteinas e usos diagnósticos e terapêuticos dos mesmos
DE68925226D1 (de) Monoklonale Antikörper
FR2697022B1 (fr) Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
BRPI9915208A (pt) preparados farmacêutico e de comprimido para a aplicação oral compreendendo moxifloxacina e seu processo de preparação.
FI900808A0 (fi) Humant mannos bindande protein.
BR9913446A (pt) Produtos de aglicona e métodos de uso
NO20015828D0 (no) Fremgangsmåter for fremstilling av 5'-nukleinsyre- proteinkonjugater
Hilleman Immunologic, chemotherapeutic and interferon approaches to control of viral disease
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
BR9106159A (pt) Polipeptideo sintetico,vacina,estojo para detectar hiv ou anticorpos contra hiv,molecula de dna,composicao farmaceutica,anticorpo ou fragmento de ligacao de antigeno do mesmo,processos de terapia ou profilaxia de infeccao hiv,de detectar hiv,de diagnosticar infeccao hiv e para a manufatura de um polipeptideo sintetico,de uma composicao farmaceutica e de um anticorpo ou fragmento de ligacao do mesmo
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
PT817851E (pt) Dna codificador do virus do papiloma humano tipo 18
FR2792831B1 (fr) Composition a destination cosmetique et/ou dietetique comprenant un melange de lycopene et d'extrait de feuille d'olivier
RU97106340A (ru) Днк, кодирующая папиломавирус типа 6а человека
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
EA200100700A1 (ru) Гены и белки и их применение
BR9609149A (pt) Modificação de drogas de polopeptídeo para aumentar o fluxo por eletrotransporte
BR9916549A (pt) Composição farmacêutica, vacina, proteìna, e, método para a prevenção ou tratamento de leishmaniose em um humano ou animal
SE9002212D0 (sv) Igg binding protein
CS55990A3 (en) Phenylhydrazones, process of their preparation and cosmetic preparations and pharmaceuticals made therefrom

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal